{"id":62059,"date":"2025-10-21T01:07:18","date_gmt":"2025-10-20T23:07:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/"},"modified":"2025-10-21T01:07:18","modified_gmt":"2025-10-20T23:07:18","slug":"samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/","title":{"rendered":"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad range of cancers<\/i><\/li>\n<li>\n<i>Collaboration will add a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis\u2019 oncology portfolio<\/i><\/li>\n<li>\n<i>Phrontline will be responsible for creating bispecific, dual-payload ADCs using its bispecific antibody and dual-linker payload (DLP) platforms<\/i><\/li>\n<li>\n<i>Samsung Bioepis receives an exclusive license from Phrontline for one TOP1i payload for development, manufacturing, and commercialization of ADC therapeutics<\/i><\/li>\n<\/ul>\n<p>\n\u00a0<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/5\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/22\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/5\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/21\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/608568\/5\/Samsung_Bioepis_Logo_2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/608568\/5\/Samsung_Bioepis_Logo_2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/608568\/21\/Samsung_Bioepis_Logo_2.jpg\"><\/a><\/p>\n<p>INCHEON, Korea &amp; SHANGHAI&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/adc?src=hash\" target=\"_blank\">#adc<\/a>&#8211;Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entered into a global collaboration agreement to develop, manufacture and commercialize two ADC assets: TJ108, bispecific and dual-payload ADC, and another asset to be named. In addition, Samsung Bioepis will receive an exclusive license from Phrontline for one topoisomerase-1 inhibitor (TOP1i) payload which is applied to Samsung Bioepis\u2019 ADC pipeline.<\/p>\n<p>\nPhrontline\u2019s TJ108 is TOP1i and tubulin inhibitor-based ADC directed against Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 3 (HER3), targets that are overexpressed in a variety of cancers, which contribute to aggressive growth and metastasis.<sup>i,ii<\/sup><\/p>\n<p>\nUnder the terms of the agreement, Phrontline will receive an upfront payment and will be eligible to receive additional milestone payments tied to development and regulatory achievements.<\/p>\n<p>\n\u201cWe are excited to partner with Phrontline in developing and advancing differentiated ADCs that target a broad range of indications,\u201d said Kyung-Ah Kim, President and Chief Executive Officer, at Samsung Bioepis. \u201cWe will continue to explore new business opportunities to address unmet needs of patients, leveraging our proven development platforms.\u201d<\/p>\n<p>\n\u201cPhrontline has honed its bispecific targeting technology to enhance payload delivery efficiency and has advanced an innovative dual-linker payload (DLP) platform that enables the simultaneous delivery of two payloads with balanced potency and distinct mechanisms of action through a branched-linker architecture, while supporting scalable and efficient one-step conjugation. This partnership accelerates our vision to establish bispecific, dual-payload ADCs as a new class of precision oncology medicines,\u201d said Zhaoyuan \u2018Tony\u2019 Chen, Founder and Chief Executive Officer of Phrontline Biopharma. \u201cTogether with Samsung Bioepis, we will scale the DLP platform \u2014 beginning with TJ108 \u2014 to address resistance, heterogeneity, and durability challenges that limit today\u2019s single-payload, single-target ADCs.\u201d<\/p>\n<p>\nSamsung Bioepis is expanding its pipeline beyond biosimilars to fulfill its mission of broadening patient access to treatments in the areas of unmet therapeutic needs. The development of ADCs could add into the company\u2019s broad spectrum of therapeutic portfolio that covers immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology.<\/p>\n<p>\n<b>About Samsung Bioepis Co., Ltd.<\/b><\/p>\n<p>\nEstablished in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world&#8217;s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungbioepis.com&amp;esheet=54341909&amp;newsitemid=20251020320860&amp;lan=en-US&amp;anchor=www.samsungbioepis.com&amp;index=1&amp;md5=939831f6e388b941f187c09c832eb7f4\" rel=\"nofollow\" shape=\"rect\">www.samsungbioepis.com<\/a> and follow us on social media \u2013 <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FSamsungBioepis&amp;esheet=54341909&amp;newsitemid=20251020320860&amp;lan=en-US&amp;anchor=X&amp;index=2&amp;md5=460cccd1beba49cd474107ad56170104\" rel=\"nofollow\" shape=\"rect\">X<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsamsungbioepis%2Flife%2F0688af2f-6f94-4c11-b993-fd1ccd896ff8%2F%3FviewAsMember%3Dtrue&amp;esheet=54341909&amp;newsitemid=20251020320860&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=ffbcf77d35119ae5258ba7205c89c8b3\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>.<\/p>\n<p>\n<b>About Phrontline Biopharma<\/b><\/p>\n<p>\nPhrontline Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China. The company\u2019s mission is to develop a new class of bispecific, dual-payload antibody\u2013drug conjugates (ADCs) designed to overcome the limitations of single-payload, single-target ADCs\u2014particularly in addressing resistance, tumor heterogeneity, and durability of response.<\/p>\n<p>\nPhrontline has established proprietary bispecific antibody and dual-linker payload (DLP) platforms that enhance payload delivery efficiency and enable the simultaneous delivery of two payloads with balanced potency and complementary mechanisms of action through a branched-linker architecture. The company is dedicated to advancing more effective and durable treatment options for patients with high unmet medical needs through its in-house innovation and integrated technology platforms.<\/p>\n<p>\nFor more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.PhrontlineBio.com&amp;esheet=54341909&amp;newsitemid=20251020320860&amp;lan=en-US&amp;anchor=www.PhrontlineBio.com&amp;index=4&amp;md5=19d5779ca48b0c02a8b6e57b6529e871\" rel=\"nofollow\" shape=\"rect\">www.PhrontlineBio.com<\/a> and follow us on LinkedIn.<\/p>\n<p>\n<sup>i<\/sup> Pastwi\u0144ska J, Kara\u015b K, Karwaciak I, Ratajewski M. Targeting egfr in melanoma \u2013 the sea of possibilities to overcome drug resistance. Biochim Biophys Acta (BBA) &#8211; Rev Cancer. (2022) 1877:188754. doi: 10.1016\/j.bbcan.2022.188754<br \/>\n<br \/><sup>ii<\/sup> Papa F, Grinda T, Rassy E, et al. Long road towards effective HER3 targeting in breast cancer. Cancer Treat Rev. 2024;129:102786. doi: 10.1016\/j.ctrv.2024.102786<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact \u2013 Samsung Bioepis<\/b><br \/>Anna Nayun Kim, <a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#58;&#110;a&#x79;&#x75;&#110;&#56;6&#x2e;&#x6b;&#105;m&#64;&#x73;&#x61;&#109;s&#x75;&#x6e;&#103;&#46;c&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">na&#121;&#117;&#x6e;&#x38;&#x36;&#x2e;ki&#109;&#64;&#x73;&#x61;&#x6d;&#x73;un&#103;&#46;&#99;&#x6f;&#x6d;<\/a><br \/>Yoon Kim, <a target=\"_blank\" href=\"&#x6d;&#x61;&#105;lt&#x6f;&#x3a;&#121;&#111;o&#x6e;&#x31;&#46;&#107;i&#x6d;&#x40;&#x73;&#97;ms&#x75;&#x6e;&#103;&#46;c&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">y&#111;&#x6f;&#x6e;1&#46;&#107;&#x69;&#x6d;&#64;&#115;&#x61;&#x6d;s&#117;&#110;&#x67;&#x2e;c&#111;&#x6d;<\/a><\/p>\n<p>\n<b>Media Contact \u2013 Phrontline Biopharma<\/b><br \/>Ying Li, <a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;Y&#105;&#x6e;&#x67;&#46;&#76;&#x69;&#64;&#80;&#x68;&#x72;o&#110;&#x74;&#x6c;i&#110;&#x65;B&#105;&#x6f;&#x2e;c&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x59;&#x69;&#110;&#103;&#46;L&#x69;&#x40;&#x50;&#104;&#114;on&#x74;&#x6c;&#x69;&#110;&#101;B&#x69;&#x6f;&#x2e;&#99;&#111;&#109;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad range of cancers Collaboration will add a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis\u2019 oncology portfolio Phrontline will be responsible for creating bispecific, dual-payload ADCs using its bispecific antibody and dual-linker payload &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62059","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad range of cancers Collaboration will add a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis\u2019 oncology portfolio Phrontline will be responsible for creating bispecific, dual-payload ADCs using its bispecific antibody and dual-linker payload ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T23:07:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/22\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors\",\"datePublished\":\"2025-10-20T23:07:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/\"},\"wordCount\":750,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020320860\\\/en\\\/2614536\\\/22\\\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/\",\"name\":\"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020320860\\\/en\\\/2614536\\\/22\\\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\",\"datePublished\":\"2025-10-20T23:07:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020320860\\\/en\\\/2614536\\\/22\\\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020320860\\\/en\\\/2614536\\\/22\\\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors - Pharma Trend","og_description":"Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad range of cancers Collaboration will add a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis\u2019 oncology portfolio Phrontline will be responsible for creating bispecific, dual-payload ADCs using its bispecific antibody and dual-linker payload ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-20T23:07:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/22\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors","datePublished":"2025-10-20T23:07:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/"},"wordCount":750,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/22\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/","url":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/","name":"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/22\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg","datePublished":"2025-10-20T23:07:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/22\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251020320860\/en\/2614536\/22\/Samsung_Bioepis_Phrontline_Signing_Ceremony_20251020.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-phrontline-announce-a-global-strategic-partnership-to-advance-best-in-class-antibody-drug-conjugate-therapeutics-for-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62059"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62059\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}